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In Brief
Burzynski et al. reveal that the
coagulation protease thrombin directly
cleaves pro-interleukin (IL)-1a, rapidly
activating the downstream inflammatory
cascade. This cleavage site in IL-1a is
conserved throughout mammals,
suggesting that this link between
coagulation and inflammation may be
relevant in multiple disease settings.
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Ancient organisms have a combined coagulation and
immune system, and although links between inflam-
mation and hemostasis exist in mammals, they are
indirect and slower to act. Here we investigated
direct links betweenmammalian immune and coagu-
lation systems by examining cytokine proproteins for
potential thrombin protease consensus sites. We
found that interleukin (IL)-1a is directly activated by
thrombin. Thrombin cleaved pro-IL-1a at a site
perfectly conserved across disparate species, indi-
cating functional importance. Surface pro-IL-1a on
macrophages and activated platelets was cleaved
and activated by thrombin, while tissue factor, a
potent thrombin activator, colocalized with pro-IL-
1a in the epidermis. Mice bearing a mutation in the
IL-1a thrombin cleavage site (R114Q) exhibited de-
fects in efficient wound healing and rapid thrombo-
poiesis after acute platelet loss. Thrombin-cleaved
IL-1a was detected in humans during sepsis, point-
ing to the relevance of this pathway for normal phys-
iology and the pathogenesis of inflammatory and
thrombotic diseases.
INTRODUCTION
With the emergence of multicellular life came a greater need to
protect against invasion by pathogens and thus the rapid evolu-
tion of the immune system. The coagulation system developed
from an early innate immune system, with blood serine proteases
diverging from complement-like proteases (Delvaeye and Con-
way, 2009). Bleeding is the primary challenge to survival after
wounding, followed by the risk of infection. Thus, activation of
inflammation during hemostasis is likely advantageous. Ancient
organisms such as horseshoe crabs utilize a combined coagula-
tion and immune system where clotting plugs wounds and en-Immunity 50, 1033–1042, A
This is an open access article undtraps pathogens (Delvaeye and Conway, 2009). Although links
between coagulation and immunity exist in mammals, they are
indirect and slower to act.
Coagulation acts immediately, with the intrinsic or extrinsic
pathway activating a protease cascade that drives rapid
thrombin activation, fibrin deposition, and platelet activation,
leading to hemostasis. Innate immunity is slower and typically re-
quires sensing of pathogen-associated molecular patterns to
activate apical cytokines, such as interleukin-1 (IL-1), to direct
inflammation and subsequent adaptive immunity (Dinarello,
2009). Inflammation induces tissue factor to promote coagula-
tion, while thrombin induces inflammation via cleavage of prote-
ase-activated receptors (PARs) (Delvaeye and Conway, 2009).
These slower kinetics could allow microbes to proliferate within,
for example, a wound. Hence, a quicker and more direct link be-
tween hemostasis and immunity in mammals would benefit
host fitness.
IL-1 is ancient with IL-1 homologues identified in echinoderms
(Beck and Habicht, 1986). IL-1 signaling via the type 1 IL-1 re-
ceptor (IL-1R1) leads to multiple inflammatory effects including
vasodilation, increased vascular permeability (Zhu et al., 2012),
cytokine secretion, leucocyte recruitment, and upregulation
of major histocompatibility complex and co-stimulatory mole-
cules (Dinarello, 2009). IL-1 also effects adaptive immunity by
enhancing Th17 differentiation and effector T cell proliferation
with Tregs present (Chung et al., 2009; Schenten et al., 2014).
These potent effects mean that IL-1 activity is tightly controlled
at multiple levels, including a receptor antagonist (IL-1RA), a
decoy receptor (IL-1R2), and expression of IL-1a (Zheng et al.,
2013; Burzynski et al., 2015) and IL-1b (Black et al., 1988) as pro-
proteins that require proteolysis for full activity. While IL-1b is
activated by complex multimeric inflammasomes, IL-1a is
cleaved by calpain (Kobayashi et al., 1990) or granzyme B (Afo-
nina et al., 2011). Importantly, increased IL-1 activity is a hallmark
of many chronic inflammatory conditions, including rheumatoid
arthritis, diabetes, and atherosclerosis.
We identified a direct link between the coagulation and
immune systems. IL-1a was activated by thrombin cleavage
at a highly conserved site, implying functional importance.
We showed key roles for thrombin-cleaved IL-1a in rapidpril 16, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 1033
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. IL-1a Is Activated by Direct
Thrombin Cleavage
(A) Protein alignment showing conservation of a (K)
PRS motif in diverse species.
(B and C) Western blots for IL-1a showing cleav-
age of recombinant p33 to an 18kDa form by
thrombin (B), and inhibition of cleavage after
mutating Arg112 to His (C).
(D) N-terminal sequencing of thrombin-cleaved
human p33 IL-1a detected one sequence (italic
underlined) corresponding to processing between
Arg112 and Ser113.
(E–G) IL-1-dependent IL-6 production by HeLa
cells incubated with calpain cleaved (E) or
thrombin cleaved (F) p33 IL-1a, ± a neutralizing
IL-1a pAb (+aAb), or increasing concentrations of
recombinant p17 or p18 (G).
(H and I) Cleavage and activation of p33 IL-1a
during clotting of platelet-rich plasma (PRP) as
shown with a cleaved IL-1a-specific ELISA (H) or
IL-1-dependent IL-6 production by HeLa cells (I), ±
a calpain inhibitor (+Ci), or an IL-1a pAb (+aAb).
(J) Mutation of Arg112 to His prevents p33 activa-
tion during clotting of PRP.
(K) Pictogram showing cleavage sites within p33
IL-1a. Data represent mean ± SEM; n = 3 (E–G, I),
n = 5 (H), n = 2 (J); p = *%0.05, **%0.01, ***%0.001;
NS = not significant. See also Figure S1.thrombopoiesis after acute platelet loss and for wound healing.
We also identified thrombin-cleaved IL-1a in humans with
sepsis-associated adult respiratory distress syndrome (ARDS).
These findings will likely have widespread implications for in-
flammatory and thrombotic diseases and normal physiology.
RESULTS
Pro-IL-1a Is Cleaved and Activated by Thrombin
We investigated direct links between mammalian immune and
coagulation systems by examining cytokine proproteins for po-
tential protease consensus sites. IL-1a contained a highly
conserved (K)PRS motif, reminiscent of a thrombin consensus,
adjacent to the calpain cleavage site (Figure 1A). This PRS site
was in 83% of mammalian species with sequences available
(Figure S1A), in all orders of mammals except marsupials, and
in highly divergent Xenarthrans (e.g., Armadillo). Thrombin treat-1034 Immunity 50, 1033–1042, April 16, 2019ment of recombinant pro-IL-1a (p33)
gave a specific fragment of 18kDa
(p18), distinct from calpain-matured IL-
1a (p17) (Figure 1B). As thrombin typically
cleaves after Arg (Gallwitz et al., 2012)
we conservatively mutated Arg to His
(R112H), which prevented cleavage (Fig-
ure 1C). Edman degradation confirmed
cleavage between Arg112 and Ser113 (Fig-
ure 1D). Cleavage of p33 IL-1awith either
calpain (Figure 1E) or thrombin (Figure 1F)
fully activated the cytokine, as measured
by bioassay with a neutralizing antibody
to prove IL-1a activity. Recombinant pro-
teins corresponding to p17 and p18showed equivalent IL-1 activity (Figure 1G). IL-1R2 could also
limit p33 IL-1a activation by thrombin (Figure S1B). p33 IL-1a
was cleaved (Figure 1H) and activated (Figure 1I) independent
of calpain during ex vivo clotting, while mutant p33 R112H was
not (Figure 1J), reinforcing the specific action of thrombin.
Thus, thrombin specifically cleaved and activated p33 IL-1a at
a conserved site adjacent to the calpain site (Figure 1K),
revealing a fundamental link between coagulation and immunity.
Macrophages, Keratinocytes, and Platelets Can Provide
Pro-IL-1a for Cleavage by Thrombin
We investigated which cell types could provide p33 IL-1a for
activation by thrombin. Macrophages and dendritic cells ex-
press p33 on their surface (Kurt-Jones et al., 1985; Fettelschoss
et al., 2011), and LPS-treated human andmouse primary macro-
phages and cell lines increased surface expression of IL-1a (Fig-
ures 2A, S1C, and S1D), which could be cleaved by thrombin
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Figure 2. Key Cell Types Contain p33 IL-1a that Can Be Cleaved by Thrombin
(A and B) Flow cytometry plots and mean fluorescence intensity (MFI) for cell surface IL-1a in murine J2 macrophages treated ± LPS (A), or LPS followed by
thrombin (+Tmb), ± a thrombin inhibitor (PPACK) (B).
(C and D) Cleaved IL-1a-specific ELISA (C) and IL-1 activity assay (D) showing release of active p18 from the surface of LPS-treated J2 macrophages into the
conditioned media by thrombin.
(E and F) Human skin sections stained (brown) for IL-1a (E) or tissue factor (F).
(legend continued on next page)
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(Figure 2B) to release active p18 into the conditioned media (Fig-
ures 2C and 2D). Epidermal keratinocytes provide barrier func-
tion that stops infection, and constitutively express IL-1a (Anttila
et al., 1990). Human and mouse skin showed IL-1a expression
specifically within the epidermis that colocalized with tissue fac-
tor (Figures 2E, 2F, S1E, and S1F), a potent activator of thrombin.
Keratinocyte lysates contained p33 IL-1a that was partially pro-
cessed by calpain, but extensively processed by thrombin (Fig-
ure 2G). Keratinocytes also secreted p33 that could be pro-
cessed by thrombin (Figure 2H), suggesting thrombin cleavage
of epidermal IL-1a after wounding could be an elegant mecha-
nism to rapidly alert the immune system and safeguard against
infection. Platelets are in close proximity to thrombin during he-
mostasis, and contain IL-1a and IL-1b (Hawrylowicz et al., 1989).
Resting platelets contained p33 IL-1a (Figure 2I), while platelet
lysates contained p33 that could be cleaved by thrombin (Fig-
ure 2J). Platelet activation with collagen or collagen-related pep-
tide (CRP) resulted in microvesiculation and surface IL-1a
expression on human (Figure 2K) and mouse (Figure S1G) plate-
lets. Similarly, platelet activation increased the amount of p33
IL-1a that thrombin could release from the surface (Figure S1H).
Thus, key cell types at sites of coagulation release and/or pre-
sent IL-1a on their surface, which can be cleaved and activated
by thrombin.
Generation of a Mouse Model in Which IL-1a Cannot Be
Activated by Thrombin
To establish in vivo relevance of p18 IL-1a we developed a
mouse model in which IL-1a cannot be activated by thrombin.
Whether mouse IL-1a requires cleavage for full activity has not
been shown. Concentration-response curves (Figure 3A) and
cleavage of p33 (Figure S2A) showed that mouse IL-1a also
required cleavage for full activity. Mouse p33 was also cleaved
(Figure 3B) and activated (Figure S2B) by thrombin, with muta-
tion of the equivalent site (R114H) reducing cleavage (Figure 3B).
Again, recombinant mouse p17 and p18 showed equivalent ac-
tivity (Figure 3C), and mouse p33 was also activated indepen-
dently of calpain during ex vivo clotting (Figure 3D). However,
the remnant thrombin cleavage of mouse R114H p33 still pro-
duced active IL-1a (Figure 3E). We tested a panel of other muta-
tions for thrombin cleavage by western (Figure S2C) and ELISA
(Figure S2D), and relative increase in activity during ex-vivo clot-
ting (Figure S2E). The R114Q mutant was resistant to thrombin
cleavage in vitro (Figure 3F) and showed no increase in activity
after clotting (Figure 3G). R114Q was cleaved by calpain (Fig-
ure 3H) and other proteases (Figure S2F) equivalently to wild
type, was expressed at the same protein level (Figure 3I), and
maintained comparable low basal activity (Figure S2G). The
R114Q point mutation was generated in the murine Il1a
locus and offspring bred to homozygosity to generate IL-1a
thrombin mutant mice (IL-1a TM). Testing macrophage-derived
p33 IL-1a revealed equivalent calpain cleavage in both geno-(G) Western blot for IL-1a in human keratinocyte necrotic lysates, ± a calpain inh
(H) Cleaved IL-1a-specific ELISA showing thrombin cleavage of p33 IL-1a within
(I) Western blot for IL-1a showing p33 within human platelets.
(J) Cleaved IL-1a-specific ELISA showing thrombin cleavage of p33 IL-1a in hum
(K) Flow cytometry for CD41 and IL-1a on resting, and collagen or collagen-relat
(C, D, J), n = 2 (H), n = 5 (K); p = *%0.05, **%0.01, ***%0.001. Scale bars repres
1036 Immunity 50, 1033–1042, April 16, 2019types, but an inability of thrombin to cleave p33 from IL-1a TM
macrophages (Figure 3J). Thrombin could not cleave surface
IL-1a from IL-1a TM macrophages, (Figure 3K). No phenotypic
difference was found between control and IL-1a TM mice with
regard to: full blood count or clotting parameters (Table S1 and
Figure S2H); IL-1a and IL-1b expression, cell surface IL-1a, IL-
1a cleavage upon necrosis or IL-1a and IL-1b release after in-
flammasome activation (Figure S3A–S3D); Ly6CHi monocytes
(Figure S3E); spleen or lymph node weight (Figure S3F and
S3G); splenic CD4 and CD8 T cell or Treg frequency (Figure S3H
and S3I); or splenic CD4 and CD8 T cell activation (Figure S3J
and S3K). This data proves that the mutation functions as shown
in vitro and did not created any general phenotypic differences.
p18 IL-1a Drives Rapid Thrombopoiesis and Wound
Healing, and Is Generated during Sepsis in Humans
Conservation of the thrombin cleavage site implies positive se-
lection and thus an advantage on fitness. IL-1a drives rapid
thrombopoiesis after acute platelet loss (Nishimura et al.,
2015), but how IL-1a is activated is unknown. We postulated
that thrombin could generate active IL-1a after platelet loss or
consumption during coagulation. We treated control and IL-1a
TM mice with anti-CD42b to deplete platelets and measured
platelet rebound over time. Platelet count between groups was
the same before depletion (Figure 4A). In control mice platelet
count was reinstated within 4–5 days (Figure 4B), followed by a
drop consistent with normal platelet turnover after IL-1a-depen-
dent fragmentation of all mature megakaryocytes (MKs) (Nishi-
mura et al., 2015). IL-1a TMmice showed delayed platelet recov-
ery with counts only returning to baseline after 10–11 days
(Figure 4B)—kinetics consistent with thrombopoietin (TPO)-
driven MK differentiation (Machlus and Italiano, 2013) and near
identical to platelet rebound in Il1r1-/- mice (Figure 4B). Bone
marrow MK number was similar between groups before platelet
depletion (Figure 4C) and repeated blood sampling had minimal
effect on platelet count in non-depleted mice (Figure S4A). The
transient increase in cleaved IL-1a in serum after platelet deple-
tion (Nishimura et al., 2015) was near absent in IL-1a TM mice,
and in control mice after thrombin inhibition (Figure 4D), support-
ing failure of thrombin to generate p18 IL-1a. Platelet depletion
caused multiple hemorrhages (Figure S4B), which could activate
prothrombin via tissue factor. This suggests thrombin activation
of IL-1a is the mechanism that induces rapid platelet production
after acute platelet consumption.
Given the colocalization of IL-1a with tissue factor in the
epidermis (Figures 2E and 2F) we examined whether failure to
generate p18 in IL-1a TM mice affects wound healing—a pro-
cess combining initial hemostasis and subsequent immune cell
recruitment to direct wound repair (Eming et al., 2014). IL-1a
TMmice showed significantly delayed excisional wound closure
at all stages of repair (Figures 4E and 4F), with a rate of wound
closure 1.8-fold slower than control mice (Figure 4G), whichibitor (+Ci), ± thrombin.
human keratinocyte conditioned media.
an platelet lysates or recombinant p33.
ed peptide (CRP) treated human platelets. Data represent mean ± SEM; n = 3
ent 100mm. See also Figure S1.
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Figure 3. Generation of a Mouse Model in which IL-1a Cannot Be Activated by Thrombin
(A) IL-1-dependent IL-6 production by murine fibroblasts incubated with increasing concentrations of recombinant mouse p17 or p33 IL-1a.
(B) Western blot for IL-1a showing thrombin cleavage of recombinant mouse wild-type p33 to a 18kDa form, but less cleavage of Arg114His p33.
(C–E) IL-1-dependent IL-6 production by murine fibroblasts incubated with increasing concentrations of recombinant mouse p17 or p18 (C), or wild-type (D) and
Arg114His mutant (E) p33 incubated with clotting platelet-rich plasma (PRP), ± a calpain inhibitor (+Ci) and/or an IL-1a pAb (+aAb).
(legend continued on next page)
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was equivalent to wound repair in Il1r1-/- mice (Figures 4F and
4G). Fewer neutrophils (Figures 4H and 4I) and monocyte/mac-
rophages (Figures 4J and 4K) were recruited to the granulation
tissue underlying IL-1a TM wounds, and less cleaved IL-1a
was released by wounded IL-1a TM skin (Figure 4L), with both
groups releasing equivalent IL-1b, and active thrombin (Fig-
ure S4C). Thrombin inhibition reduced cleaved IL-1a production
fromwounds in control mice (Figure S4D), although scarring was
similar between groups (Figure S4E). This suggests that
thrombin cleaved IL-1a is produced after epidermal injury and
that it drives immune cell recruitment and healing.
To examine whether p18 IL-1a is produced in humans in vivo,
we generated a peptide antibody specific to p18 and p33, but
not p17 (Figure S4F and S4G) and developed this into a sand-
wich ELISA specific for p18 IL-1a (Figure 4M). Generalized
sepsis activates coagulation in humans (Delvaeye and Conway,
2009), with sepsis-associated ARDS showing more severe
coagulation abnormalities (Abraham, 2000). Examination of
sera from ARDS and age-matched control individuals (Table
S2) revealed no p18 in control individuals, but p18 generation
in sepsis-associated ARDS (Figure 4N), with all patient sera
that contained p18 IL-1a also positive for microbiology in bron-
choalveolar lavage fluid (Figure 4N and Table S3). Lastly, cleaved
IL-1a level was lower during experimental endotoxemia in IL-1a
TMmice (Figure 4O), implying generation of p18 IL-1a during hu-
man sepsis and mouse endotoxemia. Outcome of endotoxemia
was unaffected in IL-1a TM mice (Figure S4H), consistent with
previous findings in Il1r1-/- mice (Kayagaki et al., 2011). Thus,
thrombin activated IL-1a drives two physiological processes
in vivo in mice and is generated in humans during generalized
infection.
DISCUSSION
Selection pressure drives biological complexity, with co-evolu-
tion of hosts and pathogens creating ever more sophisticated
defense mechanisms. Primitive genes underwent subfunctional-
ization to generate the coagulation, immune, and complement
systems we see in mammals today. Crosstalk between these
systems is thought to have evolved to increase host fitness,
but this interplay may represent conserved pathways from the
combined ancestral coagulation-immune system.
Here we revealed a direct link between the coagulation
and immune systems. IL-1a was activated by thrombin at a
conserved site, implying functional importance. Macrophages,
keratinocytes, and platelets expressed p33 IL-1a that was acti-
vated and released by thrombin. Experiments in a mouse model
in which IL-1a cannot be activated by thrombin revealed roles for
p18 IL-1a in rapid thrombopoiesis after acute platelet loss and(F) Western blot for IL-1a showing no thrombin cleavage of an Arg114Gln mutant
(G and H) IL-1-dependent IL-6 production by murine fibroblasts incubated with w
calpain (H).
(I) Western blot for IL-1a showing equivalent expression of exogenous wild-type
(J) Cleaved IL-1a-specific ELISA reporting the level of calpain or thrombin process
1a TM) mBMDMs.
(K) Flow cytometry for surface IL-1a on LPS-treated control or IL-1a TM mBM
represent mean ± SEM; n = 3 (A, E, and J), n = 2 (C and H), n = 5 (G); p = *%0.0
Table S1.
1038 Immunity 50, 1033–1042, April 16, 2019wound healing. Importantly, we also identified p18 IL-1a in hu-
mans with sepsis-associated ARDS.
pro-IL-1a contains 271 amino acids, with all cytokine activity in
the C-terminus from residue 120 onwards. Conserved regions
form the distinctive beta trefoil fold in the C-terminus, and a nu-
clear localization sequence in the N-terminus (Rivers-Auty et al.,
2018). Thus, the perfect conservation of the IL-1a PRS sequence
in 83% of mammalian species is likely due to it forming a
thrombin site under positive selection. All orders of mammal,
except marsupials, showed the PRS site, with the distant Xenar-
thrans (e.g. Armadillo) having undergone 240 million years of
divergent evolution from primates (Nishihara et al., 2009). Before
the emergence of IL-1a and IL-1b, all ancestral IL-1 sequences
are annotated as IL-1b (e.g. birds, reptiles). However, some spe-
cies contained PRS sequences and others showed high conser-
vation of PVRS adjacent to the caspase-1 site in ancestral IL-1,
and thus in a position analogous to the IL-1a PRS site. This sug-
gests the potential divergence of an ancestral IL-1 cleaved by
both caspases and thrombin, to IL-1b cleaved by caspases
and IL-1a cleaved by thrombin and calpain. Coagulation and
immunity are combined in most arthropods (Delvaeye and Con-
way, 2009), with wounding perhaps the most ancient danger
signal. In Drosophila, the Toll signaling pathway utilizes myeloid
differentiation primary response 88 (MyD88) and Toll/IL-1 recep-
tor (TIR) signaling adaptors homologous to those used by
mammalian IL-1R1. Intriguingly, cleavage of the Toll ligand
Sp€atzle to a form that induces TIR-MyD88 signaling can be via
the thrombin-like gastrulation defective, snake, and easter (Hecht
and Anderson, 1992; Kimbrell and Beutler, 2001). This suggests
that an ancient proteolytic cascade in an insect that diverged
600 million years ago still has a functional equivalent in mam-
mals today.
Conservation of the IL-1a thrombin site implies positive selec-
tion, and thus a fitness advantage. The simplest reason to
instigate an immune response during coagulation is to prevent
wound infection. As human andmouse epidermis showed coloc-
alization of IL-1a with tissue factor, any laceration damaging
cutaneous vessels would bring together p33 and active
thrombin. Indeed, slower wound healing in IL-1a TM mice, indi-
cating p18 IL-1a was required, matches the retarded healing in
Il1r1-/- mice (Lee et al., 2017). It will be interesting to see whether
other interfaces between host and the external environment
show similar expression of IL-1a and tissue factor, e.g., mucosal
epithelium. The current principal link between coagulation
and immunity is cleavage of PARs by thrombin, which produces
cytokines and inflammation. Cytokines can take 6 h before
peak production, providing time for bacterial growth. However,
IL-1 drives rapid vasodilation (Wakabayashi et al., 1991), and
increases vascular permeability via a MYD88-ARNO-ARF6p33.
ild-type or mutant p33 incubated with clotting platelet-rich plasma (G) or active
or mutant p33 in HeLa cells.
ing of p33 IL-1a derived from LPS-treated control or IL-1a thrombin mutant (IL-
DMs incubated ±thrombin (+Tmb) and ± a thrombin inhibitor (PPACK). Data
5, **%0.01, ***%0.001; NS = not significant. See also Figures S2 and S3, and
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Figure 4. p18 IL-1a Drives Rapid Thrombopoiesis and Wound Healing, and Is Generated during Sepsis in Humans
(A and B) Platelet count by flow cytometry in mice under basal conditions (A), or over time after anti-CD42b-mediated platelet depletion (B).
(C) Flow cytometry for the number of CD41+ and CD61+ MKs in the bone marrow of control and IL-1a TM mice under basal conditions.
(D) Cleaved IL-1a-specific ELISA reporting the level of cleaved IL-1a within the serum of control mice treated ±dabigatran (+Dabi) and IL-1a TM mice over time
after anti-CD42b-mediated platelet depletion.
(E–G) Representative images showing gross healing of 4mmexcisional skin wounds (E), quantitation of wound area (F) over time, and rate of closure (G) inmice as
indicated.
(legend continued on next page)
Immunity 50, 1033–1042, April 16, 2019 1039
pathway within 15 mins (Zhu et al., 2012), enabling rapid extrav-
asation of complement and leucocytes to sites of injury and/or
infection. Thus, we envisage p33 cleavage from the surface of
macrophages or platelets by thrombin to represent a rapid IL-
1-mediated defense mechanism.
Another key finding is that p18 IL-1a drove rapid platelet pro-
duction after acute platelet loss. MKs can utilize caspases to
produce platelets (Clarke et al., 2003), and IL-1a induces cas-
pase-3-dependent MK fragmentation to rapidly release platelets
in a TPO-independent manner (Nishimura et al., 2015). After
acute platelet loss, this alternative pathway quickly generates
functional platelets to enable hemostasis, with TPO maintaining
steady-state platelet count (Nishimura et al., 2015). How IL-1a is
activated in these models was unknown. We showed delayed
platelet recovery after depletion in IL-1aTM mice, which only
differ from controls by a single amino acid change that blocked
thrombin cleavage of IL-1a, suggesting p18 is generated
by thrombin after platelet loss. We propose two mechanisms
for thrombin activation: firstly, thrombin is activated when plate-
lets are ‘‘consumed’’ during hemostasis, and thrombin cleaved
IL-1a from the platelet surface; secondly, thrombocytopenia
causes microvessel leakage (purpura, petechiae) where pro-
thrombin is exposed to and activated by tissue factor. Although
purpura and petechiae are seen in skin, microvessel leakage oc-
curs systemically and thus any local source of p33 IL-1a could be
activated. In both cases, p18 IL-1a level would inversely corre-
late to platelet count. Thus, platelet loss by any cause would
lead to thrombin activation and potential cleavage of local p33
IL-1a to induce rapid platelet shedding from MKs. IL-1 also en-
ables rapid myeloid recovery after acute bone-marrow injury
(Pietras et al., 2016), suggesting that IL-1 can promote other
emergency programs after acute insults.
The identification of a direct link between the coagulation sys-
tem and the activation of the IL-1a inflammatory cascade raises
important questions. The current findings are limited to wound
healing and acute platelet loss settings, and thus it will be neces-
sary to determine the relevance of p18 IL-1a in pathological set-
tings where one might expect this pathway to be important. For
example, although we showed p18 IL-1a is generated during
sepsis-associated ARDS, it would be valuable to determine
whether p18 affects or correlates (e.g. as a biomarker) to clinical
outcome. The day-to-day heterogeneity of patients and clinical
interventions within these extreme phenotypes would require a
prospective study andmodelling (e.g., a Cox’s proportional-haz-
ard model) to identify any effect p18 contributed. Many diseases
are driven by the interplay between coagulation and inflamma-
tion. Inflammation drives atherosclerosis and IL-1a can play a
dominant role independent of inflammasomes (Menu et al.,
2011; Freigang et al., 2013), suggesting another mechanism ac-
tivates IL-1a. Plaques contain thrombin-antithrombin complexes(H–K) Representative images and quantitation of Ly6G+ neutrophils (H and I) or
wounds at the times indicated.
(L) ELISA data showing release of cleaved IL-1a or IL-1b from wounded skin.
(M) Sandwich ELISA data showing reactivity of the p18-specific ELISA to p17, p
(N and O) p18-specific ELISA data reporting level of p18 in plasma from control ind
microbiology in bronchoalveolar lavage fluid. (O) Cleaved IL-1a-specific ELISA
mice during LPS-induced endotoxemia. Data represent mean ± SEM; n = R4 (
wounds (L), n = 2 (M); p = *%0.05, **%0.01, ***%0.001; NS = not significant. See
1040 Immunity 50, 1033–1042, April 16, 2019(Borissoff et al., 2010) and show fibrin localized throughout
(Smith, 1986), implying thrombin activation occurs throughout
atherogenesis. Thus, p18 IL-1amight drive atherogenesis, which
could be tested using fat-fed IL-1a TM/Apoe-/- mice. Patients
with aneurysm have IL-1a levels directly correlated to the size
of the overlying mural thrombus, and levels fall after repair (Yates
et al., 2011), suggesting that thrombusmayproduce IL-1a in vivo.
Indeed, p18 could be produced and subsequently trapped in
developing thrombi, with potential release during fibrinolysis re-
cruiting leukocytes to help with clot resolution. These potential
effects of p18 IL-1a on thrombi could be studied with intravital
microscopy. Platelet IL-1a also drives arthritis (Boilard et al.,
2010) and cerebrovascular inflammation after ischaemia (Thorn-
ton et al., 2010), and thus platelet-derived p18 IL-1a may be
involved in these settings too. Further studies should shed light
on the relevance of thrombin-mediated IL-1a activation in these
settings.
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Image-Pro Insight 9.1 Media Cybernetics http://www.mediacy.com/imagepro
ImageJ 1.5 National Institutes of Health https://imagej.nih.gov/ij/index.html
ImageJ FibrilTool Boudaoud et al., 2014
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Other
Biopsy punch Kai Medical Cat#BP-40F
GSTrap HP column GE Cat#17-5281-01
EpiLife medium ThermoFisher Cat#MEPI500CA
CL-XPosure Film ThermoFisher Cat#34089CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Murray
Clarke (mchc2@cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
HeLa or mouse fibroblasts were cultured in DMEM, 10% FCS, 100U/ml penicillin, 0.1mg/ml streptomycin, 2mM L-glutamine. U937,
J2 immortalised macrophages and mouse BMDMs were cultured in RPMI 1640, 10% FCS, 2mM L-glutamine, 100U/ml penicillin,
0.1mg/ml streptomycin, and 50mM b-mercaptoethanol, with 15% L929 conditioned media for mBMDM differentiation. Mouse fibro-
blasts and BMDMs cultures were derived from adult male and female mice. For human monocyte-derived macrophages (hMDMs),
monocytes were isolated from whole blood (male and female adults) following citration, dextran sedimentation, and plasma-percoll
density gradient centrifugation. hMDMs were differentiated by culturing adherent monocytes (5–7 d) Iscove’s DMEM with 100U/ml
penicillin, 0.1mg/ml streptomycin, 2mM L-glutamine and 10% autologous serum, with washing and media replacement every
2 days. Keratinocytes were cultured in EpiLife media (Thermo Fisher) with Ca2+ added as indicated. All cells were grown at
37C using standard cell culture techniques and were frequently tested for mycoplasma infection. Cell lines were recently obtained
commercially (e.g. HeLa and U937) and authenticated by the company (ECACC). Primary cells were differentiated in house (e.g.
mBMDMs).
Experimental animals
All animal experiments were performed under UK Home Office licensing. For in vivo experiments males and females of at least
6 weeks of age were used, and experimental groups were age-matched. All mice were maintained in SPF conditions in IVC cages
at the University of Cambridge. Mice were maintained on a 12-hour light/dark cycle; food and water were available ad libitum. Gen-
otyping was by standard PCR protocols. Mice were bred and maintained in groups of 1-5 animals per cage; for skin wounding ex-
periments, mice were singly housed. IL-1aTMmice were generated by homologous recombination of the point mutation into exon 5
of Il1a in a C57BL/6 FLP ES cell line using an FRT flanked Neo selection cassette, and generation of chimaeras with C57BL/6J mice
(inGenious Targeting Laboratory). IL-1aTMmice were born at expected frequencies with no gross phenotype compared to littermate
controls. IL-1R1-/- mice were purchased from The Jackson Laboratory.
Human studies
Whole blood for plasma or serum, platelets, and monocytes was taken from healthy adult donors with informed consent and ethical
approval from the National Research Ethics Service. Experiments used blood from both male and female donors with no age restric-
tions (See Table S2 and S3 for ARDS patient details and clinical parameters).
METHOD DETAILS
Cell-based assays
Necrotic lysates weremade by freeze/thawing cells in liquid N2. Cells were treatedwith IL-1a (10 ng/ml; Peprotech); calpeptin (30 mM;
Enzo); LPS (1 mg/ml); nigericin (15mM; Invivogen). IL-1a-specific activity was inferred by IL-6 production from HeLa or mouse fibro-
blasts in response to test treatments ±neutralising antibody against human (1mg/ml; Peprotech) or mouse (2mg/ml; R&D) IL-1a, or
human IL-1b (1mg/ml; R&D). Conditioned media was collected, clarified, and IL-6 assayed as below.e4 Immunity 50, 1033–1042.e1–e6, April 16, 2019
In vivo experiments
Platelets were depleted by IV injection of CD42b (1.8mg/g; Emfret), with blood sampling from dorsal pedal veins. Thrombin was in-
hibited by oral gavage of dabigatran etexilate (100mg/kg). MKswere identified as FSC/SSC high, CD41+/61+ (both 1:200; Biolegend).
For wound experiments, four full-thickness excisional wounds in shaved dorsal skin of isoflurane anaesthetisedmice weremadewith
a 4 mm biopsy punch (Integra). Mice had wounds photographed including a ruler for calibration, and wound area was determined
with ImageJ. Healing rate constants were calculated by a one-phase decay model of curve fitting for wound area (GraphPad).
Skin was dissected, formalin fixed (10%; 16h) and paraffin embedded. Wound exudate was absorbed onto filter paper disks, before
soaking in PBS and separation by centrifugation. For endotoxemia, mice were injected IP with LPS (20 mg/kg; E. coli 0111:B4) and
serum collected (+6 h). Endotoxemia was graded using a standard mouse monitoring sheet.
Mouse phenotyping
Blood counts utilised a Vet ABC counter (Scil), with clotting parameters analysed by ROTEM. Spleens were sieved (70mm) before
washing (PBS; 350 g, 5 mins), re-sieving (40mm), RBC lysis (eBioscience), washing, and resuspension in FACs buffer (1% BSA,
0.05% NaN3, in PBS) or full RPMI. Cells in FACs buffer were Fc blocked (1:100; Biolegend; 10 mins, RT) before staining for T cell
activation with: anti-CD4 (1:800; eBioscience), anti-CD8 (1:100), anti-CD62L (1:80), anti-CD44 (1:400; all Biolegend), RT for
20 mins; or for Tregs with: anti-CD4 (1:800), anti-CD25 (1:80; Biolegend), RT for 20 mins, before washing, fixation, permeabilisation
(FOXP3 Fix/Perm; Biolegend), then anti-Foxp3 (1:20; Biolegend), RT for 30 mins. Cells in RPMI were treated ±ionomycin/PMA/bre-
feldin A (1:500; Biolegend), incubated (5 h, 37C), washed, resuspended in FACs buffer, Fc blocked, stained with anti-CD4 or anti-
CD8 (20 mins, RT), washed, fixed, permeabilised (Biolegend), then anti-IL-10, anti-IL-17, and anti-IFNg (all 1:100; Biolegend), RT for
30mins. For neutrophil, monocyte or Ly6C+ cells, whole blood (EDTA) was stained with anti-CD115 (1:100; eBioscience), anti-CD11b
(1:800), anti-Ly6G (1:80; both Biolegend), anti-Ly6C (1:400; abD Serotec), RT for 30 mins, before RBC lysis, washing, and analysis by
flow cytometry (Accuri C6).
Platelet experiments
Platelets were obtained by centrifugation (280g, 20min) of blood (sodium citrate; 0.38%) to give platelet-rich plasma (PRP). PRPwas
treated with p33, ± calpeptin (30mM), before addition of CaCl2 (20mM) and incubation (30 min, 37C) to produce serum. PRP was
washed by diluting 5 fold in HBSS (w/o Ca2+, pH 6.4, 4mM EDTA), centrifugation (280g, 20 min), before resuspension in HBSS.
Platelets were treated with collagen-related peptide (50 mg/ml) or collagen (1 mg/ml; Helena), incubated (4-6 h, 37C), stained with
anti-hIL-1a-FITC (1:20; R&D), anti-hCD41-PE (0.63 mg/ml; Biolegend); or anti-mIL-1a-PE (1:20; Biolegend), anti-mCD41-FITC
(1:200; Biolegend; 30 mins), before dilution (1:10; 1% BSA/PBS) and analysis by flow cytometry (Accuri C6), or thrombin treatment
of supernatants or NP-40 (0.5%/PBS) lysates. Platelet were counted in whole blood (EDTA), stained with anti-CD41-FITC (1:200;
Biolegend), diluted (1:1005; 1% BSA/PBS) and enumerated by flow cytometry.
Protein expression and purification
Human p33 (1-271), p17 (119-271), p18 (113-271) and mouse p33 (1-270), p17 (121-270) and p18 (115-270) was cloned into pGEX-
4T-3 (GE) and mutations introduced by site directed mutagenesis. For GST purification, IPTG-induced cultures (Rosetta) were lysed
in 50 mMNa2HPO4 pH 7.5, 150 mMNaCl, 1 mMDTT, 1 mM EDTA, with benzonase, lysozyme, and protease inhibitors (30 mins, RT),
clarified, loaded onto a GSTrap column (GE) using an FPLC system (AKTA pure), washed, eluted (50 mM reduced glutathione),
concentrated and dialyzed against 10 mM Tris pH 8.0, 50 mM NaCl. Protein concentration and purity was checked by Coomassie
staining and quantified with an Odyssey scanner (Licor). Proteins were stored with 10% glycerol (-80C).
Protease cleavage
p33 (20ng) was incubated in duplicate with calpain (50U; Calbiochem) in 10 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT, 2 mM CaCl2
(30 mins, RT); or restriction grade thrombin (0.09U, or as indicated; Merck) in 20 mM Tris pH 8.4, 150 mM NaCl, 2.5 mM CaCl2 (2 h,
RT). For both, an enzyme control without p33, and an incubation control without enzyme was included. p33 cleavage was antagon-
ised with a 100-fold molar excess of IL-1R2 (42 mg/ml; R&D), ± IL-1RAcP (50 mg/ml; Sino). p33 (150ng) was incubated with chymase
(0.0003 U) in 27mMTris pH 7.7, 150mMNaCl; elastase (0.03 U; Enzo) in 50mMTris pH 8.8 (both 2 h, RT); or granzymeB (16 mg/ml) in
PBS (1 h, RT). Cell-derived p33 was extracted from LPS-treated (1mg/ml; 6 h, 37C) mBMDMs or from keratinocyte conditioned me-
dia. Reactions were ±calpeptin (30mM) or ±PPACK (100mM; both Enzo).
Western blotting and Edman degradation
Westerns were performed as previously described with cells lysed directly in Laemmli buffer or RIPA (ThermoFisher) with protease
inhibitors, followed by SDS-PAGE, transfer to PVDF membrane, blocking (5% milk), incubation (16h, 4C) with human IL-1a pAb
(1:500; Peprotech), mouse IL-1a (1:500; R&D) or IL-1b pAb (1:1000; Peprotech), or a/b-tubulin pAb (1:3333; CST), washing (PBS/
Tween) and incubation (1 h, RT) with anti-rabbit HRP (1:2000; GE) or anti-goat HRP (1:2000; Jackson Immunoresearch). Visualisation
was with ECL reagent (Amersham) and X-ray film (ThermoFisher). To analyse IL-1a/b in mBMDMs, calpeptin was added before lysis
(30mM; 30 mins, 37C) and to the lysis buffer (100mM). Thrombin cleaved IL-1a was resolved, transferred to PVDF, Coomassie
stained, and 10 pmol of the C-terminal band sent for Edman degradation (Alta Bioscience).Immunity 50, 1033–1042.e1–e6, April 16, 2019 e5
Cytokine measurement and ELISA development
Samples were analysed by plate ELISA for human or mouse IL-1a (both Peprotech), cytometric bead ELISA for human or mouse IL-6
(BD), IL-1a or IL-1b (ThermoFisher), or mouse TAT complexes (Abcam). Specificity of human (Figure S4I) or mouse (Figure S4J)
cleaved-IL-1a specific ELISA was proven with recombinant and/or cell-derived p17 and p33. The p18-specific antibody was
produced in rabbits using SAPFSFLS-Ahx-KC-KLH for immunisation (Innovagen), and affinity purified. For indirect ELISA, plates
(Maxisorb) were coated with peptide, p17, p18 or p33 (1 mg/ml; 16h, RT), washed (0.05% Tween/PBS), blocked (1% BSA; 1 h,
RT), washed, serial diluted antiserum added (2 h, RT), washed, anti-rabbit-HRP antibody (1:5000; Dako) added (1 h, RT), washed
and developed with TMB. For the p18-specific sandwich ELISA, plates (Costar) were coated with IL-1a capture antibody (R&D;
1mg/ml; 16h, RT), washed, blocked, samples added (2 h, RT), washed, biotinylated p18 detection antibody added (400 ng/ml; 2 h,
RT), washed, anti-rabbit biotin added (1:7500; Dako; 1 h, RT), washed, streptavidin-HRP added (1:200; R&D; 1 h, RT), and developed
with TMB (ThermoFisher). Plates were measured at 450nm (BioTek) and data analysed using a 4 parameter logistic standard curve.
Human plasma was taken with informed consent and ethical approval, and cytokines measured (Mesoscale Discovery).
Cell and tissue staining
Paraffin embedded human (Abcam) or mouse skin sections were cleared, antigen retrieved with sodium citrate (10mM; pH 6), block-
ing in H2O2 (3%; 10 mins) and then horse serum (5%; 1 h), incubated with anti-IL-1a (1:100); anti-tissue factor (1:25; both Abcam);
anti-Ly6G (1:500; Biolegend); anti-Mac-3 (1:400; BD); or isotype controls (Abcam; all 16 h, 4C). Mac-3 and Ly6G sections were incu-
bated with biotinylated 2ry antibodies (1:500; 1 h), ABComplex (30 mins), and visualised with DAB (all Vector), while IL-1a and tissue
factor were visualised with Envision Kit (Dako) or amouse/rabbit HRP/DAB kit (Abcam). Collagenwas stainedwith picosirius red (Pol-
ysciences). Imaging used a BX51 (Olympus) and Image-Pro Insight 9.1 software (MediaCybernetics). Collagen fibre anisotropy was
measured with ImageJ FibrilTool. Surface IL-1a on Accutase harvested, Fc blocked (1:100; Biolegend) human/mouse cells was
stained with anti-hIL-1a-FITC (1:20; R&D), or anti-mIL-1a-PE (1:20; Biolegend) before flow cytometry.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± SEM, unless otherwise stated. Assays producing continuous data, with the exception of flow cytom-
etry and in vivo mouse experiments, were in duplicate. n = individual experimental replicate. Parametric test analysis of continuous
data used ANOVA or Student’s t-test (GraphPad). Non continuous data was analysed with Spearman’s rank correlation coefficient.
Significance is as stated, but always p = <0.05. Non-significant (NS) data was considered anything p = >0.05. Datasets from the cur-
rent study are available on reasonable request.e6 Immunity 50, 1033–1042.e1–e6, April 16, 2019
